Mostrar el registro sencillo del ítem
dc.contributor.author | Ayala-Suarez, Ruben | |
dc.contributor.author | Gracia-Ruíz de Alda, María | |
dc.contributor.author | Díez-Fuertes, Francisco | |
dc.contributor.author | Calonge, Esther | |
dc.contributor.author | de la Torre-Tarazona, Humberto Erick | |
dc.contributor.author | Capa, Laura | |
dc.contributor.author | Alcamí, José | |
dc.date.accessioned | 2020-09-14T07:38:42Z | |
dc.date.available | 2020-09-14T07:38:42Z | |
dc.date.issued | 2020-07-31 | |
dc.identifier.citation | J Clin Med. 2020 Jul 31;9(8):2452. | es_ES |
dc.identifier.issn | 2077-0383 | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/11008 | |
dc.description | Factor de impacto: 4,242 Q1 | |
dc.description.abstract | Long-term non-progressors (LTNP) and elite controllers (EC) represent spontaneous natural models of efficient HIV-1 response in the absence of treatment. The main purposes of this work are to describe the miRNome of HIV-1 infected patients with different extreme phenotypes and identify potentially altered pathways regulated by differentially expressed (DE) miRNAs. The miRNomes from peripheral blood mononuclear cells (PBMCs) of dual phenotype EC-LTNP or LTNP with detectable viremia and HIV-infected patients with typical progression before and after treatment, were obtained through miRNA-Seq and compared among them. The administration of treatment produces 18 DE miRNAs in typical progressors. LTNP condition shows 14 DE miRNA when compared to typical progressors, allowing LTNP phenotype differentiation. A set of four miRNAs: miR-144-3p, miR-18a-5p, miR-451a, and miR-324 is strongly downregulated in LTNP and related to protein regulation as AKT, mTOR, ERK or IKK, involved in immune response pathways. Deregulation of 28 miRNA is observed between EC-LTNP and viremic-LTNP, including previously described anti-HIV miRNAs: miR-29a, associated with LTNP phenotype, and miR-155, targeting different pre-integration complexes such as ADAM10 and TNPO3. A holistic perspective of the changes observed in the miRNome of patients with different phenotypes of HIV-control and non-progression is provided. | es_ES |
dc.description.sponsorship | This study has been conducted within the Spanish AIDS Research Network (RIS), funded by Instituto de Salud Carlos III (Plan Estatal de I+D+I 2013-2016) and co-funded by European Regional Development Fund (ERDF) “A way to build Europe” (RD12/0017/0015 and RD16CIII/0002/0001 projects), and the European Union’s Horizon 2020 Research and Innovation Programme under grant number 681137. The HIV BioBank, integrated in the Spanish AIDS Research Network, is partially funded by the RD16/0025/0019 project as part of the Plan Nacional R + D + I and cofinanced by ISCIII- Subdirección General de Evaluación and el Fondo Europeo de Desarrollo Regional (FEDER). R.A.-S. was supported by the Ministry of Innovation, Science and Universities predoctoral funding (FPU18/05527) and H.E.T.-T. by the ISCIII-PFIS predoctoral program (FI14CIII/00014). | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Multidisciplinary Digital Publishing Institute (MDPI) | es_ES |
dc.type.hasVersion | VoR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject.mesh | HIV-1 infection | es_ES |
dc.subject.mesh | biomarker discovery | es_ES |
dc.subject.mesh | differential expression | es_ES |
dc.subject.mesh | elite controllers | es_ES |
dc.subject.mesh | long-term non-progressors | es_ES |
dc.subject.mesh | miRNA-Seq | es_ES |
dc.subject.mesh | miRNome | es_ES |
dc.title | Insight in miRNome of Long-Term Non-Progressors and Elite Controllers Exposes Potential RNAi Role in Restraining HIV-1 Infection | es_ES |
dc.type | journal article | es_ES |
dc.rights.license | Atribución 4.0 Internacional | * |
dc.identifier.pubmedID | 32751854 | es_ES |
dc.format.volume | 9 | es_ES |
dc.format.number | 8 | es_ES |
dc.format.page | 2452 | es_ES |
dc.identifier.doi | 10.3390/jcm9082452 | es_ES |
dc.contributor.funder | Unión Europea. Comisión Europea. H2020 | |
dc.contributor.funder | Instituto de Salud Carlos III | |
dc.contributor.funder | Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) | |
dc.contributor.funder | Ministerio de Ciencia, Innovación y Universidades (España) | |
dc.description.peerreviewed | Sí | es_ES |
dc.identifier.e-issn | 2077-0383 | es_ES |
dc.relation.publisherversion | https://doi.org/10.3390/jcm9082452 | es_ES |
dc.identifier.journal | Journal of clinical medicine | es_ES |
dc.repisalud.centro | ISCIII::Centro Nacional de Microbiología | es_ES |
dc.repisalud.institucion | ISCIII | es_ES |
dc.relation.projectID | info:eu_repo/grantAgreement/ES/681137 | es_ES |
dc.relation.projectID | info:eu_repo/grantAgreement/ES/RD16/0025/0019 | es_ES |
dc.relation.projectID | info:eu_repo/grantAgreement/ES/RD16CIII/0002/0001 | es_ES |
dc.relation.projectID | info:eu_repo/grantAgreement/ES/RD12/0017/0015 | es_ES |
dc.relation.projectID | info:eu_repo/grantAgreement/ES/FPU18/05527 | es_ES |
dc.relation.projectID | info:eu_repo/grantAgreement/ES/FI14CIII/00014 | es_ES |
dc.rights.accessRights | open access | es_ES |